MedTrace Logo

A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

NCT00336700 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-09-19

Study results available
· View outcomes & findings →

Summary

Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed by single agent erlotinib for a total of 12 months.

Conditions

Interventions

DRUG

Gemcitabine

1500mg/m2 IV over 150 min IV q 2 weeks 4 months

DRUG

Erlotinib

150 mg/d Daily, oral 12 months

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Herbert J. Zeh, III MD, FACS

    lead OTHER

Principal Investigators

  • Herb Zeh, M.D. · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00336700 on ClinicalTrials.gov